Buy Semaglutide Online

Semaglutide research peptide for sale: 10mg, 5mg and 6mg vial sizes. Sort: cost per month, price per vial or cost per mg with COAs to buy from USA sources.

Buy Semaglutide 10mg,5mg or 6mg vials online with discount codes. Semaglutide for research purposes listed across multiple vendors to get the cheapest 10mg, 5mg or other vial size.

How much does Semaglutide cost per month?

An illustrative Semaglutide cost model works out to about $4.30 per month: EZ Peptides's listed 100 mg purchase quantity at $331.20 with code wpa10, divided into 0.3 mg amounts once weekly. This quantity provides 333.3 nominal portions — about 333.3 weeks at the selected cadence, before preparation losses or stability limits — for roughly $0.99 per week or $4.30 per 4.33-week month. Vial count and milligrams per vial must be checked separately. This is illustrative arithmetic combining independently selected lifetime modal inputs, not a verified most-common joint protocol. The amount distribution includes 6,408 calculator runs; overall cadence comes from 743 separate lifetime frequency responses across amounts. Calculator inputs are not confirmed administration or recommendations.

Use the live cost-per-month card to change nominal purchase quantity, amount, cadence and vendor strategy. Recorded purity can be compared separately; it is not independent verification or a quality guarantee. Confirm package composition and checkout price with the vendor.

About Semaglutide

FDA-approvedAlso known as: Ozempic · Wegovy · Rybelsus

Semaglutide is the GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus, and one of the most-sourced research peptides for weight-management and metabolic studies. It ships as a lyophilized powder reconstituted with bacteriostatic water before use.[1]

What to check before you buy Semaglutide:

  • A third-party COA showing ≥99% purity by HPLC with mass-spec confirmation of the 31-amino-acid sequence.
  • A COA dated within the last 6–12 months matching the batch and vial size you are buying.
  • Accurate vial fill against the label (a 5mg vial should assay close to 5mg). Under-filled or mislabeled vials are a common quality failure and break your reconstitution math.

The SUSTAIN program established efficacy in type 2 diabetes,[2] STEP-1 (Wilding et al., NEJM 2021) reported ~14.9% mean weight reduction at 68 weeks in adults with obesity at 2.4mg weekly,[3] and SELECT (Lincoff et al., NEJM 2023) showed a 20% reduction in major adverse cardiovascular events in adults with established CVD and overweight/obesity.[4] FLOW reported kidney-outcome benefits in T2D with chronic kidney disease.

Regulatory: FDA-approved as Ozempic, Wegovy, and Rybelsus. Research-grade semaglutide sold for in vitro / non-clinical use only.

Read the full mechanism & research breakdown

Semaglutide: Mechanisms, Half-Life & Research Data

A skimmable deep dive into how Semaglutide works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.

How it works

Semaglutide is a 31-amino-acid synthetic analog of native glucagon-like peptide-1 (GLP-1) that binds the GLP-1 receptor with high affinity.[5] Activating that receptor slows gastric emptying, amplifies glucose-dependent insulin release from the pancreas, suppresses glucagon, and acts on hypothalamic appetite centers to reduce hunger and food intake. Two structural changes from native GLP-1 — an amino-acid substitution at position 8 that resists DPP-4 degradation, and a C-18 fatty-diacid sidechain attached at position 26 that binds circulating albumin — extend the half-life to roughly 7 days and support once-weekly subcutaneous dosing.[5] An oral formulation (Rybelsus) is co-formulated with the absorption enhancer SNAC, which transiently raises gastric pH so a small fraction of the peptide can be absorbed intact across the stomach wall.

Active research areas

  • Type 2 diabetes (SUSTAIN)
    The SUSTAIN program of Phase 3 trials established A1C reductions of roughly 1.4–1.8% at 0.5–1.0mg weekly across monotherapy, add-on, and head-to-head comparisons, and supported the original 2017 Ozempic approval.[2]
  • Obesity (STEP)
    STEP-1 reported mean weight reduction of approximately 14.9% at 68 weeks on the 2.4mg arm in adults with obesity but without diabetes,[3] and STEP-3 showed that pairing semaglutide with intensive behavioural therapy produced roughly 16.0% mean weight reduction at 68 weeks.[12]
  • Cardiovascular outcomes (SELECT and SUSTAIN-6)
    SELECT reported a 20% reduction in major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) over a median 39.8 months in adults with established cardiovascular disease and overweight/obesity but without diabetes,[4] extending the earlier SUSTAIN-6 cardiovascular signal in T2D.[6]
  • Kidney outcomes in T2D (FLOW)
    FLOW reported a 24% reduction in the composite of major kidney disease events (kidney failure, ≥50% eGFR decline, kidney death, or cardiovascular death) in adults with T2D and chronic kidney disease, leading the trial to be stopped early for benefit.[8]
  • Metabolic dysfunction-associated steatohepatitis (MASH)
    A Phase 2 trial reported that 59% of participants on the 0.4mg daily arm achieved NASH resolution without worsening fibrosis at 72 weeks, versus 17% on placebo, but the trial did not show a statistically significant improvement in fibrosis stage.[9]
  • Early Alzheimer's disease (EVOKE)
    EVOKE and EVOKE+ are large Phase 3 trials testing whether once-daily oral semaglutide slows the progression of early symptomatic Alzheimer's disease, with the primary endpoint being change on the Clinical Dementia Rating–Sum of Boxes scale at 104 weeks; primary readouts are expected in 2026.[10]
  • Addiction and reward signalling
    GLP-1 receptors are expressed in the mesolimbic reward circuit, and pre-clinical and early human work on the class — including a randomised exenatide trial in alcohol use disorder that showed a benefit in the higher-BMI subgroup[11] — has prompted active randomised trials of semaglutide specifically for alcohol and nicotine use disorder.
Open questions & leading hypotheses (3)
  • Hypothesis: Semaglutide's cardiovascular benefit in SELECT is driven primarily by weight loss rather than by direct receptor effects on the vasculature.
    Evidence: The cardiovascular event reduction in SELECT tracked weight loss and metabolic improvements across pre-specified subgroups.[4] Counter-evidence: the cardiovascular benefit appeared earlier than the full weight-loss trajectory would predict, and GLP-1 receptors are expressed in the heart and vasculature; class-level work suggests anti-inflammatory and natriuretic effects independent of weight. The relative contribution of weight loss vs. direct receptor effects has not been isolated in a controlled trial that matches arms for weight loss.
  • Hypothesis: A meaningful share of the weight lost on semaglutide is lean body mass, raising long-term concerns about sarcopenia and functional decline.
    Evidence: Body-composition substudies of STEP-1 reported that roughly 39% of total weight lost was lean tissue (with a comparable proportional preservation of lean mass to fat mass), which is broadly in line with dietary weight-loss interventions of similar magnitude.[3][7] Counter-evidence: lean mass is not the same thing as functional muscle, and the long-term implications in older adults — and after rebound weight regain following discontinuation, which is well-documented[7] — have not been characterised in controlled trials.
  • Hypothesis: GLP-1 receptor signalling in the brain produces clinically meaningful benefit in addictions and in early Alzheimer's disease, not just in metabolic disease.
    Evidence: GLP-1 receptors are expressed in mesolimbic reward circuits and in hippocampal and cortical regions; epidemiologic signals and small randomised trials in the class suggest reduced craving and consumption in alcohol use disorder,[11] and the EVOKE program is the first adequately-powered test of cognitive benefit.[10] Counter-evidence: most existing addiction data is for older GLP-1 molecules (exenatide, liraglutide) and is mixed; no Phase 3 readout in Alzheimer's or addiction has yet been published, and effect sizes outside metabolic disease may be much smaller.
What community users report

Anecdotal — not controlled-trial evidence

Across r/Semaglutide and r/Ozempic, users running both prescription and research-grade protocols most often report rapid appetite suppression beginning within the first one to two weeks, a quieting of intrusive thoughts about food (the now-common phrase "food noise reduction"), and a side-effect profile dominated by nausea, constipation, and sulphur burps that frequently forces slower titration than the SUSTAIN or STEP trial protocols use.[13][14] A widely-discussed pattern is meaningful rebound hunger and partial-to-full weight regain after discontinuation, which is consistent with the published STEP-1 extension data showing that participants regained roughly two-thirds of lost weight over 52 weeks off drug.[7] Smaller cohorts describe reduced cravings for alcohol or nicotine, which is consistent with the pre-clinical reward-circuit literature but has not been validated in a Phase 3 trial. **These reports are anecdotal and have not been validated in controlled trials.** They are useful for understanding what people who have already chosen to use semaglutide are experiencing, but they do not establish that any specific titration schedule, off-label use, or research-grade protocol is safe or effective.

Sources & references (14)

Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.

  1. [1]FDA approval letter, Wegovy (semaglutide), June 2021 link
  2. [2]Sorli C et al. SUSTAIN 1 — Efficacy and safety of semaglutide once weekly in T2D. Lancet Diabetes Endocrinol 2017;5:251–260. · PMID: 28110911 link
  3. [3]Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). NEJM 2021;384:989–1002. · PMID: 33567185 link
  4. [4]Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023;389:2221–2232. · PMID: 37952131 link
  5. [5]Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem 2015;58:7370–7380. · PMID: 26308095 link
  6. [6]Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). NEJM 2016;375:1834–1844. · PMID: 27633186 link
  7. [7]Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553–1564. · PMID: 35441470 link
  8. [8]Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). NEJM 2024;391:109–121. · PMID: 38785209 link
  9. [9]Newsome PN et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. NEJM 2021;384:1113–1124. · PMID: 33185364 link
  10. [10]ClinicalTrials.gov: EVOKE (NCT04777396) — Semaglutide in early Alzheimer's disease. link
  11. [11]Klausen MK et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight 2022;7:e159863 — class-level GLP-1 evidence for addiction signalling; semaglutide-specific AUD trials are ongoing. · PMID: 36066977 link
  12. [12]Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults with Overweight or Obesity (STEP-3). JAMA 2021;325:1403–1413. · PMID: 33625476 link
  13. [13]Community report — r/Semaglutide weekly experience threads (subreddit), accessed May 2026. link
  14. [14]Community report — r/Ozempic dose titration and side-effect discussions (subreddit), accessed May 2026. link

What Semaglutide Costs Right Now

WPA currently tracks Semaglutide from 12 distinct vendors across 28 separate Semaglutide listings. In-stock Semaglutide vials run from $26.10 to $674.99 — a 25.9x spread for the same compound. Ameano Peptides holds the lowest sticker price at $26.10. Normalized to milligrams, Semaglutide costs $3.31/mg to $32.30/mg on this page. The best per-milligram value is the listed 100 mg purchase quantity from EZ Peptides.

Semaglutide is stocked in 7 sizes: 10 mg listed quantity; vial count not recorded; 100 mg listed quantity; vial count not recorded; 15 mg listed quantity; vial count not recorded; 20 mg listed quantity; vial count not recorded; 2 mg listed quantity; vial count not recorded; 50 mg listed quantity; vial count not recorded; 5 mg listed quantity; vial count not recorded. Because vials of different strengths rarely scale linearly in price, the per-milligram column is the only fair way to rank them.

Ranked by true cost per milligram, the Semaglutide listings WPA tracks are: EZ Peptides — 100mg at $331.20 ($3.31/mg), COA purity 99.62%; Ameano Peptides — 10mg at $34.20 ($3.42/mg), COA purity 99.63%; EZ Peptides — 10mg at $43.20 ($4.32/mg), COA purity 99.62%; Modified Aminos — 10mg at $44.99 ($4.50/mg), COA purity 99.00%; Peptira — 20mg at $101.15 ($5.06/mg), COA purity 99.77%.

Semaglutide COA Coverage Across Tracked Vendors

25 of the 28 tracked Semaglutide listings (89%) are marked as having COA availability in WPA's listing data; this marker is not independent verification. A purity value is recorded for 24 listings; purity alone does not establish identity or independent testing. The recorded purity values range from 99.00% to 100.00%. 21 listings record more Semaglutide in the vial than the label claims; check the vendor's report and batch before drawing conclusions. The latest COA date recorded in WPA's listing data is 8/26.

To assess a COA, inspect the actual report for the independent lab, test date, and a batch and vial size matching the Semaglutide offer. WPA's listing fields do not establish that a report was independently verified.

Semaglutide Calculator Input Observations

In lifetime Semaglutide calculator inputs, 250mcg is the most frequent entered amount (1,254 of 6,408 runs). Separately, Weekly (1x/wk) is the most frequent overall cadence (634 of 741 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 250mcg, Weekly (1x/wk) is most frequent (139 of 164 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. As nominal quantity arithmetic only, 100 mg of listed product divided by 0.25 mg gives roughly 400 portions before preparation losses. This does not establish vial count, stability after preparation, or cycle length.

Semaglutide Discount Codes

28 of the 28 tracked Semaglutide listings carry a WPA researcher discount code. The largest live discount is 50% off. Every price and per-milligram figure on this page is the post-discount number, so you are never comparing a discounted listing against an undiscounted one. Codes change and some exclude sale items or carry order minimums.

About Semaglutide

Semaglutide is the GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus, and one of the most-sourced research peptides for weight-management and metabolic studies. It ships as a lyophilized powder reconstituted with bacteriostatic water before use.

Semaglutide is tracked under the Weight Loss category on WPA. Its reported half-life is ~7 days. Calculator inputs do not establish why a cadence was selected or validate a protocol. FDA-approved as Ozempic, Wegovy, and Rybelsus.

How to Read the Semaglutide Comparison

  • Price per milligram — Every Semaglutide listing is normalized to $3.31/mg-style unit pricing, so a small cheap vial cannot hide a worse real cost than a larger one.
  • COA metadata and purity — 25 Semaglutide listings are marked for COA availability, and 24 have a recorded purity value. These fields do not independently verify a report.
  • Vials sizes — The Semaglutide comparison includes 2mg, 5mg, 10mg, 15mg, 20mg, 50mg, and 100mg listed purchase quantities. Check package composition separately.
  • Stock status — Live in-stock state for each Semaglutide listing, refreshed on a recurring basis.

Frequently Asked Questions: Semaglutide

Is it legal and safe to buy Semaglutide for research?

In the US, Semaglutide is sold strictly as a research chemical — legal to buy for laboratory research but not approved for human use. Research-grade semaglutide is the same peptide as the approved GLP-1 drug but is sold for laboratory use only and is not FDA-approved in this form. The real variable isn't legality, it's quality: unverified suppliers can ship underdosed, impure, or mislabeled material. WPA records COA-related listing fields where supplied, but does not independently verify every report. Inspect the actual batch report and its laboratory, identity testing, and date before drawing conclusions. Right now that screen covers 28 Semaglutide listings from 12 vendors.

How do I verify a Semaglutide COA so I'm not getting an underdosed vial?

A Certificate of Analysis (COA) may report tests for a specific Semaglutide batch. Check that the report identifies the compound (actually semaglutide, not a generic GLP-1 or an underdosed substitute), names the laboratory, describes the test method and result, and matches the offered batch and date. A recorded purity value or COA-availability flag in WPA's listing data is not independent verification. Open the vendor listing and inspect the actual report before drawing conclusions. For Semaglutide specifically, 25 of 28 tracked listings (89%) are marked as having COA availability in WPA's listing data; that marker is not independent verification. A purity value is separately recorded for 24 listings; purity alone does not establish identity or independent testing. The latest COA date recorded in the listing data is 8/26.

Which Semaglutide vendor should I pick?

There's no single "best" Semaglutide vendor — it depends on what you weigh most. WPA ranks tracked listings using recorded purity and date fields where available, visitor click activity, price, stock status, and discount data; this ranking is not independent verification of a report. Semaglutide is sold by nearly every vendor, so price spreads are wide — lean on the $/mg ranking and COA recency to separate genuine value from cut-rate underfilled vials. 12 vendors currently carry Semaglutide, and EZ Peptides holds the best true value at $3.31/mg on the 100 mg listed purchase quantity. Review the actual report and confirm its batch details before making a decision.

How much does Semaglutide cost — and how do I know I'm not overpaying?

Judge Semaglutide by true price per milligram, not the sticker price on one vial — a cheap small vial often costs more per mg than a larger one. Because the typical research dose is tiny, a single 10 mg vial stretches a long way, making semaglutide one of the cheapest GLP-1s per cycle. Tracked Semaglutide listings currently run $3.31/mg to $32.30/mg across 2mg, 5mg, 10mg, 15mg, 20mg, 50mg, 100mg listed purchase quantities (not necessarily single vials). WPA normalizes tracked listings to $/mg, and the live cost-per-month card estimates your spend at the most common dose. The one catch: the lowest $/mg sometimes means buying a bigger vial than your cycle needs.

How much Semaglutide do I need for one full cycle?

In lifetime Semaglutide calculator inputs, 250mcg is the most frequent entered amount (1,254 of 6,408 runs). Separately, Weekly (1x/wk) is the most frequent overall cadence (634 of 741 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 250mcg, Weekly (1x/wk) is most frequent (139 of 164 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. Dividing the listed 100 mg purchase quantity by 0.25 mg gives roughly 400 nominal portions before preparation losses; vial count and stability after preparation are separate questions. A cycle requires an independently chosen amount, cadence and time horizon; calculator observations do not supply those decisions. Compare nominal package quantities and model your own selections in the cost card.

Are discount codes available for Semaglutide?

Participating Semaglutide vendors may offer WPA researcher discount codes. Codes can change, exclude sale items or carry order minimums. 28 of the 28 tracked Semaglutide listings carry a code right now, the largest worth 50% off. Each listing shows the recorded code and discounted price where available; confirm the actual package and checkout terms with the vendor.

Is research semaglutide the same as Ozempic or Wegovy?

Chemically, research-grade semaglutide is the same peptide as the active ingredient in Ozempic and Wegovy. Everything around it differs: the branded products are FDA-approved, made under pharmaceutical GMP, supplied in pre-filled pens, and prescribed with medical oversight. Research vials are sold for laboratory use only, are not FDA-approved, and come with none of that oversight — which is exactly why an independent, recent third-party COA is the one thing you should never skip.

Lowest priced Semaglutide peptide for sale?

To surface the lowest priced Semaglutide for sale, WPA continuously compares 14 USA suppliers and 956 "for research" products, ranking every verified Semaglutide listing by true cost so the cheapest vials rise to the top. The lowest priced single Semaglutide vial currently starts at $26.10. We currently track 28 Semaglutide products in our system. Pricing is generally refreshed weekly as vendors update stock, prices, and discount codes.